Women Health Market - 2024-2032
The Women Health Market was valued at US$ 47.64 billion in 2024 and is anticipated to reach US$ 76.35 billion by 2032, at a CAGR of 0.056 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Women Health Market.
This report delivers a comprehensive overview of the Women Health Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Women Health Market. The Women Health Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2032.
Women Health Market Scope:
By Treatment Type
This report delivers a comprehensive overview of the Women Health Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Women Health Market. The Women Health Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2032.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Women Health Market.
This report delivers a comprehensive overview of the Women Health Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Women Health Market. The Women Health Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2032.
Women Health Market Scope:
By Treatment Type
- Hormonal Therapy
- Bone Health Agents
- Pain and Symptom Management
- Metabolic Agents
- Nutrition Supplements
- Others
- Thyroid Disorders
- Gynecological Disorders
- Cancer
- Bone Disorders
- Others
- Bayer AG
- Agile Therapeutics
- Amgen Inc.
- Lupin
- Sandoz AG
- Otsuka Pharmaceutical Co., Ltd.
- Nestle.
- Radius Health
- Eli Lilly and Company
- Seed Health
This report delivers a comprehensive overview of the Women Health Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Women Health Market. The Women Health Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2032.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Increase Your Customer Base by 3X using our Partner Identification tool
- Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
- Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
- Prioritize partners by strategic fit rather than general capability.
- Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
- Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
- White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
- Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
- Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
- Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
1. METHODOLOGY AND SCOPE
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Snippet by Treatment Type
3.2. Snippet by Disease Indication
3.3. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising awareness among women
4.1.2. Restraints
4.1.2.1. High Costs Associated with Women’s Medicine
4.1.3. Opportunity
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Patent Analysis
5.5. Regulatory Analysis
5.6. SWOT Analysis
5.7. Unmet Needs
6. BY TREATMENT TYPE
6.1. Introduction
6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
6.1.2. Market Attractiveness Index, By Treatment Type
6.2. Hormonal Therapy*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.2.3. Estrogen Therapy
6.2.4. Progesterone Therapy
6.2.5. Combination Therapy
6.2.6. Thyroid Replacement Therapy
6.2.7. Others
6.3. Bone Health Agents
6.4. Pain and Symptom Management
6.5. Metabolic Agents
6.6. Nutrition Supplements
6.7. Others
7. BY DISEASE INDICATION
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
7.1.2. Market Attractiveness Index, By Disease Indication
7.2. Thyroid Disorders*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Gynecological Disorders
7.3.1. PMS
7.3.2. PCOD
7.3.3. Uterine Fibroids
7.3.4. Endometriosis
7.3.5. Others
7.4. Cancer
7.5. Bone Disorders
7.6. Others
8. BY REGION
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.5.1. U.S.
8.2.5.2. Canada
8.2.5.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.5.1. Germany
8.3.5.2. U.K.
8.3.5.3. France
8.3.5.4. Spain
8.3.5.5. Italy
8.3.5.6. Rest of Europe
8.4. South America
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.5.1. Brazil
8.4.5.2. Argentina
8.4.5.3. Rest of South America
8.5. Asia-Pacific
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.5.1. China
8.5.5.2. India
8.5.5.3. Japan
8.5.5.4. South Korea
8.5.5.5. Rest of Asia-Pacific
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
9. COMPETITIVE LANDSCAPE
9.1. Competitive Scenario
9.2. Market Positioning/Share Analysis
9.3. Mergers and Acquisitions Analysis
10. COMPANY PROFILES
10.1. Bayer AG*
10.1.1. Company Overview
10.1.2. Product Portfolio and Description
10.1.3. Financial Overview
10.1.4. Key Developments
10.2. Agile Therapeutics
10.3. Amgen Inc.
10.4. Lupin
10.5. Sandoz AG
10.6. Otsuka Pharmaceutical Co., Ltd.
10.7. Nestl?.
10.8. Radius Health
10.9. Eli Lilly and Company
10.10. Seed Health (*LIST NOT EXHAUSTIVE)
11. APPENDIX
11.1. About Us and Services
11.2. Contact Us
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Snippet by Treatment Type
3.2. Snippet by Disease Indication
3.3. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising awareness among women
4.1.2. Restraints
4.1.2.1. High Costs Associated with Women’s Medicine
4.1.3. Opportunity
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Patent Analysis
5.5. Regulatory Analysis
5.6. SWOT Analysis
5.7. Unmet Needs
6. BY TREATMENT TYPE
6.1. Introduction
6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
6.1.2. Market Attractiveness Index, By Treatment Type
6.2. Hormonal Therapy*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.2.3. Estrogen Therapy
6.2.4. Progesterone Therapy
6.2.5. Combination Therapy
6.2.6. Thyroid Replacement Therapy
6.2.7. Others
6.3. Bone Health Agents
6.4. Pain and Symptom Management
6.5. Metabolic Agents
6.6. Nutrition Supplements
6.7. Others
7. BY DISEASE INDICATION
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
7.1.2. Market Attractiveness Index, By Disease Indication
7.2. Thyroid Disorders*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Gynecological Disorders
7.3.1. PMS
7.3.2. PCOD
7.3.3. Uterine Fibroids
7.3.4. Endometriosis
7.3.5. Others
7.4. Cancer
7.5. Bone Disorders
7.6. Others
8. BY REGION
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.5.1. U.S.
8.2.5.2. Canada
8.2.5.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.5.1. Germany
8.3.5.2. U.K.
8.3.5.3. France
8.3.5.4. Spain
8.3.5.5. Italy
8.3.5.6. Rest of Europe
8.4. South America
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.5.1. Brazil
8.4.5.2. Argentina
8.4.5.3. Rest of South America
8.5. Asia-Pacific
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.5.1. China
8.5.5.2. India
8.5.5.3. Japan
8.5.5.4. South Korea
8.5.5.5. Rest of Asia-Pacific
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
9. COMPETITIVE LANDSCAPE
9.1. Competitive Scenario
9.2. Market Positioning/Share Analysis
9.3. Mergers and Acquisitions Analysis
10. COMPANY PROFILES
10.1. Bayer AG*
10.1.1. Company Overview
10.1.2. Product Portfolio and Description
10.1.3. Financial Overview
10.1.4. Key Developments
10.2. Agile Therapeutics
10.3. Amgen Inc.
10.4. Lupin
10.5. Sandoz AG
10.6. Otsuka Pharmaceutical Co., Ltd.
10.7. Nestl?.
10.8. Radius Health
10.9. Eli Lilly and Company
10.10. Seed Health (*LIST NOT EXHAUSTIVE)
11. APPENDIX
11.1. About Us and Services
11.2. Contact Us
